FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021498934> ?p ?o ?g. }

• W2021498934 endingPage "e52655" @default.
• W2021498934 startingPage "e52655" @default.
• W2021498934 abstract "Despite high cure rates for pediatric B-lineage acute lymphoblastic leukemia (B-ALL), short-term and long-term toxicities and chemoresistance are shortcomings of standard chemotherapy. Immunotherapy and chemoimmunotherapy based on monoclonal antibodies (mAbs) that target cell surface antigens with restricted expression in pediatric B-ALL may offer the potential to reduce toxicities and prevent or overcome chemoresistance. The receptor tyrosine kinase ROR1 has emerged as a candidate for mAb targeting in select B-cell malignancies.Using flow cytometry, Western blotting, immunohistochemistry, and confocal immunofluorescence microscopy, we analyzed the cell surface expression of ROR1 across major pediatric ALL subtypes represented by 14 cell lines and 56 primary blasts at diagnosis or relapse as well as in normal adult and pediatric tissues. Cell surface ROR1 expression was found in 45% of pediatric ALL patients, all of which were B-ALL, and was not limited to any particular genotype. All cell lines and primary blasts with E2A-PBX1 translocation and a portion of patients with other high risk genotypes, such as MLL rearrangement, expressed cell surface ROR1. Importantly, cell surface ROR1 expression was found in many of the pediatric B-ALL patients with multiply relapsed and refractory disease and normal karyotype or low risk cytogenetics, such as hyperdiploidy. Notably, cell surface ROR1 was virtually absent in normal adult and pediatric tissues.Collectively, this study suggests that ROR1 merits preclinical and clinical investigations as a novel target for mAb-based therapies in pediatric B-ALL. We propose cell surface expression of ROR1 detected by flow cytometry as primary inclusion criterion for pediatric B-ALL patients in future clinical trials of ROR1-targeted therapies." @default.
• W2021498934 created "2016-06-24" @default.
• W2021498934 creator A5017638182 @default.
• W2021498934 creator A5026882105 @default.
• W2021498934 creator A5044521397 @default.
• W2021498934 creator A5065812703 @default.
• W2021498934 creator A5065906655 @default.
• W2021498934 creator A5083416957 @default.
• W2021498934 creator A5086969450 @default.
• W2021498934 creator A5090223620 @default.
• W2021498934 date "2012-12-20" @default.
• W2021498934 modified "2023-10-17" @default.
• W2021498934 title "Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies" @default.
• W2021498934 cites W1578606547 @default.
• W2021498934 cites W1587946844 @default.
• W2021498934 cites W1861074833 @default.
• W2021498934 cites W1971424591 @default.
• W2021498934 cites W1975711182 @default.
• W2021498934 cites W1992073540 @default.
• W2021498934 cites W1993649303 @default.
• W2021498934 cites W2009811887 @default.
• W2021498934 cites W2018946767 @default.
• W2021498934 cites W2020362172 @default.
• W2021498934 cites W2024149750 @default.
• W2021498934 cites W2029215138 @default.
• W2021498934 cites W2043649175 @default.
• W2021498934 cites W2046596094 @default.
• W2021498934 cites W2056561005 @default.
• W2021498934 cites W2066064966 @default.
• W2021498934 cites W2066508515 @default.
• W2021498934 cites W2067893295 @default.
• W2021498934 cites W2086297371 @default.
• W2021498934 cites W2099348990 @default.
• W2021498934 cites W2104235597 @default.
• W2021498934 cites W2106606248 @default.
• W2021498934 cites W2116266522 @default.
• W2021498934 cites W2118241155 @default.
• W2021498934 cites W2120104555 @default.
• W2021498934 cites W2121635715 @default.
• W2021498934 cites W2133950529 @default.
• W2021498934 cites W2138255423 @default.
• W2021498934 cites W2145132518 @default.
• W2021498934 cites W2149052195 @default.
• W2021498934 cites W2166836693 @default.
• W2021498934 cites W3083881843 @default.
• W2021498934 cites W4232414730 @default.
• W2021498934 cites W4255252731 @default.
• W2021498934 doi "https://doi.org/10.1371/journal.pone.0052655" @default.
• W2021498934 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3527582" @default.
• W2021498934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23285131" @default.
• W2021498934 hasPublicationYear "2012" @default.
• W2021498934 type Work @default.
• W2021498934 sameAs 2021498934 @default.
• W2021498934 citedByCount "43" @default.
• W2021498934 countsByYear W20214989342013 @default.
• W2021498934 countsByYear W20214989342014 @default.
• W2021498934 countsByYear W20214989342015 @default.
• W2021498934 countsByYear W20214989342016 @default.
• W2021498934 countsByYear W20214989342017 @default.
• W2021498934 countsByYear W20214989342018 @default.
• W2021498934 countsByYear W20214989342019 @default.
• W2021498934 countsByYear W20214989342020 @default.
• W2021498934 countsByYear W20214989342021 @default.
• W2021498934 countsByYear W20214989342022 @default.
• W2021498934 countsByYear W20214989342023 @default.
• W2021498934 crossrefType "journal-article" @default.
• W2021498934 hasAuthorship W2021498934A5017638182 @default.
• W2021498934 hasAuthorship W2021498934A5026882105 @default.
• W2021498934 hasAuthorship W2021498934A5044521397 @default.
• W2021498934 hasAuthorship W2021498934A5065812703 @default.
• W2021498934 hasAuthorship W2021498934A5065906655 @default.
• W2021498934 hasAuthorship W2021498934A5083416957 @default.
• W2021498934 hasAuthorship W2021498934A5086969450 @default.
• W2021498934 hasAuthorship W2021498934A5090223620 @default.
• W2021498934 hasBestOaLocation W20214989341 @default.
• W2021498934 hasConcept C1491633281 @default.
• W2021498934 hasConcept C159654299 @default.
• W2021498934 hasConcept C196166836 @default.
• W2021498934 hasConcept C203014093 @default.
• W2021498934 hasConcept C40722700 @default.
• W2021498934 hasConcept C502942594 @default.
• W2021498934 hasConcept C542903549 @default.
• W2021498934 hasConcept C54355233 @default.
• W2021498934 hasConcept C553184892 @default.
• W2021498934 hasConcept C71924100 @default.
• W2021498934 hasConcept C86803240 @default.
• W2021498934 hasConceptScore W2021498934C1491633281 @default.
• W2021498934 hasConceptScore W2021498934C159654299 @default.
• W2021498934 hasConceptScore W2021498934C196166836 @default.
• W2021498934 hasConceptScore W2021498934C203014093 @default.
• W2021498934 hasConceptScore W2021498934C40722700 @default.
• W2021498934 hasConceptScore W2021498934C502942594 @default.
• W2021498934 hasConceptScore W2021498934C542903549 @default.
• W2021498934 hasConceptScore W2021498934C54355233 @default.
• W2021498934 hasConceptScore W2021498934C553184892 @default.
• W2021498934 hasConceptScore W2021498934C71924100 @default.
• W2021498934 hasConceptScore W2021498934C86803240 @default.
• W2021498934 hasIssue "12" @default.

• next